Company Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.
In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria.
It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 330 |
| CEO | Kristin Yarema |
Contact Details
Address: 9390 Towne Centre Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 779 3100 |
| Website | poseida.com |
Stock Details
| Ticker Symbol | PSTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001661460 |
| CUSIP Number | 73730P108 |
| ISIN Number | US73730P1084 |
| Employer ID | 47-2846548 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristin Yarema Ph.D. | President, Chief Executive Officer and Director |
| Mark J. Gergen J.D. | Executive Chairman of the Board |
| Johanna M. Mylet CPA | Chief Financial Officer |
| Loren Wagner | Chief Operations Officer |
| Kristin Martin | Chief People and Administration Officer |
| Alexander Chapman | Senior Vice President of Investor Relations and Corporate Communications |
| Harry J. Leonhardt Esq., J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Dr. Devon J. Shedlock Ph.D. | Chief Scientific Officer of Cell Therapy |
| Lisa Portale | Senior Vice President of Regulatory Affairs |
| Dr. Jeffrey W. Winkelman J.D., Ph.D. | Senior Vice President and Chief Patent Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 30, 2024 | 8-K | Current Report |
| Aug 14, 2024 | EFFECT | Notice of Effectiveness |
| Aug 8, 2024 | UPLOAD | Filing |
| Aug 5, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 5, 2024 | 10-Q | Quarterly Report |
| Aug 5, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |
| Jun 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 14, 2024 | 10-Q | Quarterly Report |